Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA)

The purpose of this study is to evaluate the long-term safety and efficacy of the Xact? Rapid Exchange Carotid Stent System used in conjunction with the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5) and the Emboshield® BareWire? Rapid Exchange Embolic Protection System (Generation 3), in the treatment of atherosclerotic carotid artery disease in high-surgical risk subjects.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • device : Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Ronald Dalman 6507255227

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: